Sobi sold!Thanks for the ride! My guess is that there is not much more that I can get out of this one.
0.74USD
237.77 MUSD
2.18 BUSD
181.34 M
About Swedish Orphan Biovitrum AB
Sector
CEO
Guido Oelkers
Headquarters
Solna
Website
Employees (FY)
1.77 K
Founded
2001
ISIN
SE0000872095
FIGI
BBG000TXXCX6
Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. It operates through the Haematology, Immunology, and Specialty Care segments. The Haemotology segment focuses on haemophilia medicines Elocta and Alprolix. The immunology segment offers treatment for serious, disabling, and life-threatening diseases. The Specialty Care segment specializes in the treatment of genetic and metabolic diseases. The company was founded in 2001 and is headquartered in Solna, Sweden.
Swedish Orphan Biovitrum (SOBI.ST) breakout from consolidationSanofi's bid yesterday for SOBI's partner Bioverativ at a 60%+ premium is highly supportive for SOBI's valuation. Strong future in haemophilia products Eloctate and Alprolix. As the European territory (SOBI territory) launches were two years later than the US, SOBI's sales are at an earlier stage, a
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of BIOVF is 22.87 USD — it has decreased by 8.52% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Swedish Orphan Biovitrum AB stocks are traded under the ticker BIOVF.
Swedish Orphan Biovitrum AB is going to release the next earnings report on Apr 25, 2024. Keep track of upcoming events with our Earnings Calendar.
BIOVF stock is 9.31% volatile and has beta coefficient of 0.58. Check out the list of the most volatile stocks — is Swedish Orphan Biovitrum AB there?
One year price forecast for Swedish Orphan Biovitrum AB has a max estimate of 33.85 USD and a min estimate of 26.08 USD.
BIOVF earnings for the last quarter are 0.05 USD whereas the estimation was 0.03 USD which accounts for 46.77% surprise. Estimated earnings for the next quarter are 0.35 USD. See more details about Swedish Orphan Biovitrum AB earnings.
Swedish Orphan Biovitrum AB revenue for the last quarter amounts to 471.32 M USD despite the estimated figure of 415.07 M USD. In the next quarter revenue is expected to reach 671.14 M USD.
Yes, you can track Swedish Orphan Biovitrum AB financials in yearly and quarterly reports right on TradingView.
BIOVF stock has fallen by 8.52% compared to the previous week, the month change is a 17.70% fall, over the last year Swedish Orphan Biovitrum AB has showed a 13.37% decrease.
BIOVF net income for the last quarter is 101.27 M USD, while the quarter before that showed 8.57 M USD of net income which accounts for 1.08 K% change. Track more Swedish Orphan Biovitrum AB financial stats to get the full picture.
Today Swedish Orphan Biovitrum AB has the market capitalization of 7.91 B, it has increased by 0.89% over the last week.
No, BIOVF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BIOVF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Swedish Orphan Biovitrum AB stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 1.77 K employees. See our rating of the largest employees — is Swedish Orphan Biovitrum AB on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Swedish Orphan Biovitrum AB technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Swedish Orphan Biovitrum AB stock shows the buy signal. See more of Swedish Orphan Biovitrum AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Swedish Orphan Biovitrum AB future price: according to them, BIOVF price has a max estimate of 33.85 USD and a min estimate of 26.08 USD. Read a more detailed Swedish Orphan Biovitrum AB forecast: see what analysts think of Swedish Orphan Biovitrum AB and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Swedish Orphan Biovitrum AB EBITDA is 730.97 M USD, and current EBITDA margin is 35.37%. See more stats in Swedish Orphan Biovitrum AB financial statements.